Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

CBAK Energy's Q1 2026 revenue nearly doubles, driven by strong battery and raw materials sales.

Company Fundamentals
18 May 2026
Cbak Energy Technology, Inc.
View Source
Bullish
pluang ai news

CBAK Energy Technology reported a 99.3% year-over-year revenue increase to $69.62 million in Q1 2026, fueled by expanded production capacity and strong demand in light electric vehicles and battery raw materials. The battery segment grew 84.3%, with light electric vehicle sales surging 441.6%, while the raw materials segment more than doubled revenues and turned profitable. Despite a net loss of $9.29 million due to ramp-up costs and raw material price pressures, the company expects margin improvements as new production lines mature and pricing adjusts. Cash reserves and operating cash flow remain strong, supporting growth and inventory buildup for rising demand.

More News

Arbor Biotechnologies names Mathew Pletcher as new Chief Scientific Officer to boost gene editing pipeline.

Arbor Biotechnologies names Mathew Pletcher as new Chief Scientific Officer to boost gene editing pipeline.

Arbor Biotechnologies appointed Mathew Pletcher, Ph.D., as its new Chief Scientific Officer, succeeding John Murphy who is retiring. Dr. Pletcher brings nearly 20 years of experience in gene therapy and rare diseases, having held leadership roles at ...

Company Fundamentals
Bullish
12 minutes ago
NRx Pharmaceuticals beats EPS estimates but misses revenue, awaits FDA decisions on key drugs.

NRx Pharmaceuticals beats EPS estimates but misses revenue, awaits FDA decisions on key drugs.

NRx Pharmaceuticals reported a quarterly EPS of -$0.04, beating estimates and improving from last year, but revenue fell short at $1.07 million. The company is preparing for an FDA decision on its Preservative-Free Ketamine and has FDA clearance for ...

Company Fundamentals
Bullish
1 hour ago
Rein Therapeutics raises $57.5M in stock offering to fund Phase 2 trial for lung fibrosis drug.

Rein Therapeutics raises $57.5M in stock offering to fund Phase 2 trial for lung fibrosis drug.

Rein Therapeutics completed a $57.5 million underwritten public offering by selling 57.5 million shares at $1.00 each, including the full exercise of an over-allotment option. The proceeds will fund the Phase 2 clinical trial of their drug LTI-03 for...

Company Fundamentals
Bullish
2 hours ago
Streamex pays April 2026 gold-backed yield to GLDY token holders from gold leasing program.

Streamex pays April 2026 gold-backed yield to GLDY token holders from gold leasing program.

Streamex Corp. announced its second monthly yield distribution for GLDY, a gold-backed tokenized security, covering April 2026. The yield is generated through Streamex's institutional gold leasing program, which currently earns an annualized lease yi...

Company Fundamentals
Bullish
2 hours ago
TOYO reports Q1 2026 revenue up 177% and net income of $28.4M, reaffirming strong 2026 outlook.

TOYO reports Q1 2026 revenue up 177% and net income of $28.4M, reaffirming strong 2026 outlook.

TOYO Co., Ltd announced a 177% increase in Q1 2026 revenue to $142.8 million, driven by higher solar cell and module sales. Net income rose to $28.4 million from a loss of $3.7 million in Q1 2025, with EBITDA improving significantly. The company reaf...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App